slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 237,541-237,570
Pages 10,126
Rows per page 30
Component
237,541-237,570 of 303,780
11
TTM = Trailing Twelve MonthsAmazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
12
The chart highlights a 4% year-over-year increase in FCF, with a footnote clarifying that operating cash flow increased 36% Y/Y.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
15
The chart highlights the trend in share dilution over five quarters.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
16
Amazon | Results Presentation Deck | 19 slidesAmazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
17
Values are in millions (MM).Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
18
TTM stands for Trailing Twelve Months, though the table presents discrete quarterly data points.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
19
TTM stands for Trailing Twelve Months. The table reconciles Operating Cash Flow to a specific adjusted Free Cash Flow metric.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations 1 hit
01
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
03
The slide uses a three-column layout to summarize key strategic pillars: clinical assets, development timeline, and platform pedigree.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
04
The slide uses a hub-and-spoke diagram to connect Boron to four therapeutic areas (Oncology, Inflammatory Response, Parasites, Bacterial Diseases).AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
05
The slide uses a Gantt-style chart to show the development stage of multiple drug candidates.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
06
The slide uses a timeline-based framework to categorize R&D milestones and market opportunities.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
07
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
08
The slide combines a problem statement (clinical unmet need) with a market sizing chart.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Market Size1 hit
09
Includes clinical trial timeline diagram and outcome tables.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Market Size1 hit
10
The table uses blue highlighting to emphasize the higher severity metrics in the EBO Ph 2 group.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
11
LSM = Least squares mean. PRO = Patient-Reported Outcome. The slide highlights alignment with FDA guidance for primary endpoints in NTM trials.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
12
The chart highlights a statistically significant improvement (p=0.036) at month 6.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Voice Of Customer1 hit
13
The chart shows a longitudinal comparison of two treatment groups over 6 months. The p-value of 0.043 indicates nominal statistical significance for the difference in mean change from baseline.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Voice Of Customer1 hit
14
The slide presents TEAE (Treatment-emergent adverse events) and SAE (Serious adverse events) data.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
15
Focuses on PRO (Patient Reported Outcomes) as a primary endpoint for the EBO-301 trial.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
16
The slide presents three line charts (A, B, C) comparing PBS, IMI (Imipenem), and two doses of EBO (EBO25, EBO50) over 4 weeks.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
17
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
18
Includes a map showing global distribution and a specific callout for US endemicity.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
19
The slide uses a central hub-and-spoke style diagram to connect funding sources with market potential.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
20
The chart shows Log10 CFU counts in lungs for various treatment groups compared to untreated control.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
22
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
23
Includes a disease progression timeline diagram on the right.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
24
The slide uses a hub-and-spoke diagram to show the global burden relative to specific regions.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
25
The slide uses a dot map to visualize geographic distribution of infections.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit